Weekly Intelligence · 6 articles

Vet Industry Intel: Feb 22 – Feb 28, 2026

High-signal veterinary industry stories triangulated from multiple sources, scored for relevance, and grouped by event type.

Acquisitions & M&A (1) Regulatory & Policy (2) Products & Technology (3)

Acquisitions & M&A

Feb 23, 2026 [10/10] DVM360

Covetrus and MWI Animal Health agree to merge in $3.5 billion deal

Covetrus and MWI Animal Health have agreed to merge in a $3.5 billion deal, as reported by DVM360.

Covetrus · MWI Animal Health · DVM360

Regulatory & Policy

Feb 26, 2026 [8/10] DVM360

FDA approves first and only second-generation Janus kinase inhibitor

The FDA has approved the first and only second-generation Janus kinase inhibitor for veterinary use, according to reports by DVM360.

FDA · DVM360

Feb 23, 2026 [8/10] Veterinary Practice News

FDA issues Emergency Use Authorizations for NWS meds for dogs, cats

The FDA has issued Emergency Use Authorizations for New World Screwworm (NWS) medications for dogs and cats.

FDA · Veterinary Practice News

Products & Technology

Feb 27, 2026 [8/10] DVM360

Wrap up: Merck Animal Health’s atinvicitinib tablets receive FDA approval, and other news

Merck Animal Health received FDA approval for its atinvicitinib tablets, as highlighted in veterinary industry news.

Merck Animal Health · FDA · DVM360

Feb 26, 2026 [8/10] Pet Age

FDA Approves NUMELVI from Merck Animal Health for the Control of Pruritus in Dogs

The FDA approved NUMELVI from Merck Animal Health for the control of pruritus in dogs.

Merck Animal Health · FDA · Pet Age

Feb 27, 2026 [7/10] PR Newswire

Gallant Announces First-of-Its-Kind Partnership with MWI Animal Health to Deliver Anticipated FDA-Conditionally Approved Stem Cell Therapy into Veterinary Clinics

Gallant has partnered with MWI Animal Health to distribute its anticipated FDA-conditionally approved stem cell therapy directly to veterinary clinics.

Gallant · MWI Animal Health